{"title":"鸢尾素通过抑制HMGB1/Nrf2/GPX4通路减轻糖尿病肾病小管上皮铁下垂。","authors":"Dan Wang, Furong Zhu, Miao Miao Shao, Huimei Zang, Xue Xia","doi":"10.1007/s00210-025-04681-z","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic nephropathy (DN) is a global health threat with limited therapeutic interventions. Irisin, a myokine derived from FNDC5, has been implicated in glucose homeostasis and anti-diabetic effects; however, its precise mechanistic role in glucose metabolism regulation remains elusive. This study elucidates the specific role of Irisin in mitigating diabetic renal tubular epithelial injury, with a focus on its regulatory mechanisms under glucotoxic conditions. Utilizing streptozotocin (STZ)-induced type 1 diabetes (T1D) mouse models and high glucose (HG)-stimulated HK-2 cells, we demonstrated that STZ-induced DN mice exhibited renal dysfunction, oxidative stress, and iron accumulation. Sustained HG exposure downregulated glutathione peroxidase 4 (GPX4) and xCT while upregulating Ptgs2 and FPN1, indicative of Ferroptosis initiation. Irisin treatment significantly attenuated these pathological changes and ameliorated renal tubular epithelial injury. Mechanistically, this protective effect was mediated through the activation of high-mobility group box-1 (HMGB1), a damage-associated regulator, as observed in both in vivo and in vitro studies. Furthermore, we identified the nuclear translocation of Nrf2 and its downstream target GPX4 in vitro. Specific interference with Nrf2, through both knockdown and overexpression experiments under HG conditions, further demonstrated Irisin's regulatory role on HMGB1. This was validated by assessing tubular epithelial cell viability, alongside cellular levels of malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and Fe<sup>2+</sup> content. Notably, Nrf2 co-transfection nullified the protective effects of Irisin, exacerbating Ferroptosis markers. Collectively, our findings reveal that Irisin protects against glucotoxicity-induced renal injury by inhibiting tubular epithelial Ferroptosis via the HMGB1/Nrf2/GPX4 axis, thereby proposing a novel therapeutic target for DN.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Irisin attenuates tubular epithelial ferroptosis in diabetic kidney disease by inhibiting the HMGB1/Nrf2/GPX4 pathway.\",\"authors\":\"Dan Wang, Furong Zhu, Miao Miao Shao, Huimei Zang, Xue Xia\",\"doi\":\"10.1007/s00210-025-04681-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Diabetic nephropathy (DN) is a global health threat with limited therapeutic interventions. Irisin, a myokine derived from FNDC5, has been implicated in glucose homeostasis and anti-diabetic effects; however, its precise mechanistic role in glucose metabolism regulation remains elusive. This study elucidates the specific role of Irisin in mitigating diabetic renal tubular epithelial injury, with a focus on its regulatory mechanisms under glucotoxic conditions. Utilizing streptozotocin (STZ)-induced type 1 diabetes (T1D) mouse models and high glucose (HG)-stimulated HK-2 cells, we demonstrated that STZ-induced DN mice exhibited renal dysfunction, oxidative stress, and iron accumulation. Sustained HG exposure downregulated glutathione peroxidase 4 (GPX4) and xCT while upregulating Ptgs2 and FPN1, indicative of Ferroptosis initiation. Irisin treatment significantly attenuated these pathological changes and ameliorated renal tubular epithelial injury. Mechanistically, this protective effect was mediated through the activation of high-mobility group box-1 (HMGB1), a damage-associated regulator, as observed in both in vivo and in vitro studies. Furthermore, we identified the nuclear translocation of Nrf2 and its downstream target GPX4 in vitro. Specific interference with Nrf2, through both knockdown and overexpression experiments under HG conditions, further demonstrated Irisin's regulatory role on HMGB1. This was validated by assessing tubular epithelial cell viability, alongside cellular levels of malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and Fe<sup>2+</sup> content. Notably, Nrf2 co-transfection nullified the protective effects of Irisin, exacerbating Ferroptosis markers. Collectively, our findings reveal that Irisin protects against glucotoxicity-induced renal injury by inhibiting tubular epithelial Ferroptosis via the HMGB1/Nrf2/GPX4 axis, thereby proposing a novel therapeutic target for DN.</p>\",\"PeriodicalId\":18876,\"journal\":{\"name\":\"Naunyn-Schmiedeberg's archives of pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Naunyn-Schmiedeberg's archives of pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00210-025-04681-z\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-025-04681-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Irisin attenuates tubular epithelial ferroptosis in diabetic kidney disease by inhibiting the HMGB1/Nrf2/GPX4 pathway.
Diabetic nephropathy (DN) is a global health threat with limited therapeutic interventions. Irisin, a myokine derived from FNDC5, has been implicated in glucose homeostasis and anti-diabetic effects; however, its precise mechanistic role in glucose metabolism regulation remains elusive. This study elucidates the specific role of Irisin in mitigating diabetic renal tubular epithelial injury, with a focus on its regulatory mechanisms under glucotoxic conditions. Utilizing streptozotocin (STZ)-induced type 1 diabetes (T1D) mouse models and high glucose (HG)-stimulated HK-2 cells, we demonstrated that STZ-induced DN mice exhibited renal dysfunction, oxidative stress, and iron accumulation. Sustained HG exposure downregulated glutathione peroxidase 4 (GPX4) and xCT while upregulating Ptgs2 and FPN1, indicative of Ferroptosis initiation. Irisin treatment significantly attenuated these pathological changes and ameliorated renal tubular epithelial injury. Mechanistically, this protective effect was mediated through the activation of high-mobility group box-1 (HMGB1), a damage-associated regulator, as observed in both in vivo and in vitro studies. Furthermore, we identified the nuclear translocation of Nrf2 and its downstream target GPX4 in vitro. Specific interference with Nrf2, through both knockdown and overexpression experiments under HG conditions, further demonstrated Irisin's regulatory role on HMGB1. This was validated by assessing tubular epithelial cell viability, alongside cellular levels of malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and Fe2+ content. Notably, Nrf2 co-transfection nullified the protective effects of Irisin, exacerbating Ferroptosis markers. Collectively, our findings reveal that Irisin protects against glucotoxicity-induced renal injury by inhibiting tubular epithelial Ferroptosis via the HMGB1/Nrf2/GPX4 axis, thereby proposing a novel therapeutic target for DN.
期刊介绍:
Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.